Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Ortho Clinical Diagnostics Holdings Plc (OCDX)

Sector - Healthcare

Price chart

-5.12%
Return from IPO

Company News

IPO Profile

About company

They are a pure-play in vitro diagnostics (“IVD”) business driven by their credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides their priorities as an organization. As a leader in IVD, they impact approximately 800,000 patients every day. They are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. Their global infrastructure and commercial reach allow them to serve these markets with significant scale. They have an intense focus on the customer. They support their customers with high quality diagnostic instrumentation, a broad test portfolio and market leading service. Their products deliver consistently fast, accurate and reliable results that allow clinicians to make better-informed treatment decisions. Their business model generates significant recurring revenues and strong cash flow streams from ongoing sales of high margin consumables. In 2019, these consumables contributed more than 90% of their total revenue and approximately 93% of their core revenue.
Industry
In Vitro & In Vivo Diagnostic Substances
CEO CFO
Chris Smith Joseph Busky
Employees Founded
4500 1939

Contacts

Address: 1001 Route 202 Raritan, New Jersey 08869

Telephone: 908-218-8000

Web page: http://www.orthoclinical.com

IPO information

Expected Date 1/28/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 70
Shares Revised (MM) 76
Expected offer amount (MM) $1505
Realized offer amount(MM) $1292

Financial Data (last reporting year)

Market Cap (MM) $4656.47
Revenues (MM) $1723.3
Net Income (Loss) (MM) $-172.6

Voting

What do you think will happen with the OCDX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ BofA Securities/ Goldman Sachs/ Barclays/ Morgan Stanley/ Citigroup/ Credit Suisse/ UBS Investment Bank/ Evercore ISI/ Piper Sandler
CO-Managers
ING/ Macquarie Capital/ / Nomura/ TCG Capital Markets/ Drexel Hamilton/ H.C. Wainwright/ Ramirez & Co./ Siebert Williams Shank

Sector: Healthcare

Tweets about $OCDX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats